Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas
Status:
Completed
Trial end date:
2020-11-05
Target enrollment:
Participant gender:
Summary
A Phase 1/2a, dose-escalation study of FF-10502-01 in Patients with Advanced Solid Tumors and
Lymphomas. A total of up to 9 cohorts will be enrolled in Phase 1 to establish the MTD. Phase
2 will consist of 2 cohorts: Cohort 1 will include subjects with Pancreatic Cancer. Cohort 2
will include subjects with another tumor type enrolled in the Phase 1 dose-escalation phase
who have demonstrated Clinical Benefit by Week 16.